Morgan L. Paull
Morgan L. Paull has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Travis A. Ahn-Horst
BridgeBio Pharma, Inc Palo Alto California USA
2 shared publications - Alan X. Ji
BridgeBio Pharma, Inc Palo Alto California USA
1 shared publication - Daniel S. Weaver
SRI International, Menlo Park, CA 94025, USA
1 shared publication - Derek N. Macklin
Department of Bioengineering, Stanford University, Stanford, CA 94305, USA
1 shared publication - Eran Agmon
Center for Cell Analysis and Modeling, University of Connecticut Health
1 shared publication - Gwanggyu Sun
Department of Bioengineering, Stanford University, Stanford, CA 94305, USA
1 shared publication
Latest Publications
- Open Access
- 8 June 2026
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (6) , e70277
Evaluation of the Current ATTR ‐ CM Treatment Landscape via a Mathematical Model of TTR Dissociation and Amyloid Formation
Transthyretin amyloid cardiomyopathy (ATTR‐CM) is a progressive, often fatal disease arising from the dissociation of circulating transthyretin (TTR) tetramers into monomers that misfold and form amyloid fibrils that deposit in the myocardium and other tissues. Approved treatment paradigms involve tetramer stabilization with small molecules or TTR knockdown via RNA interference. Despite the clinical success of these drugs across several metrics (including all‐cause mortality and cardiovascular hospitalization), gaps remain in understanding how measurable biological changes, such as differences in serum TTR concentration, translate into reductions in amyloid deposition. To address this, we built a mechanistic mathematical model of the TTR system that integrates heterogeneous data sources, including in vitro assays and clinical data, and recapitulates key features of ATTR‐CM disease biology. The model predicts “monomer efflux,” the rate at which unfolded monomers could potentially form amyloid, as a proxy for the pathogenic mechanism, which is difficult to measure. Model‐predicted monomer efflux linearly correlated with reported rates of change in clinical measures, supporting its validity as a comparative metric. The model showed that monomer efflux is nearly twice as high in hereditary ATTR‐CM (ATTRv) as in wild‐type ATTR‐CM (ATTRwt). Comparison of treatment modalities showed that acoramidis yields the greatest reduction in monomer efflux (96% in ATTRwt, 95% in ATTRv) due to rapid, near‐complete stabilization of TTR. This framework enables quantitative interrogation of the disease system and principled comparisons across modalities that may help inform treatment selection.
- 8 June 2026
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (6) , e70277
Open AccessEvaluation of the Current ATTR ‐ CM Treatment Landscape via a Mathematical Model of TTR Dissociation and Amyloid Formation
Transthyretin amyloid cardiomyopathy (ATTR‐CM) is a progressive, often fatal disease arising from the dissociation of circulating transthyretin (TTR) tetramers into monomers that misfold and form amyloid fibrils that deposit in the myocardium and other tissues. Approved treatment paradigms involve tetramer stabilization with small molecules or TTR knockdown via RNA interference. Despite the clinical success of these drugs across several metrics (including all‐cause mortality and cardiovascular hospitalization), gaps remain in understanding how measurable biological changes, such as differences in serum TTR concentration, translate into reductions in amyloid deposition. To address this, we built a mechanistic mathematical model of the TTR system that integrates heterogeneous data sources, including in vitro assays and clinical data, and recapitulates key features of ATTR‐CM disease biology. The model predicts “monomer efflux,” the rate at which unfolded monomers could potentially form amyloid, as a proxy for the pathogenic mechanism, which is difficult to measure. Model‐predicted monomer efflux linearly correlated with reported rates of change in clinical measures, supporting its validity as a comparative metric. The model showed that monomer efflux is nearly twice as high in hereditary ATTR‐CM (ATTRv) as in wild‐type ATTR‐CM (ATTRwt). Comparison of treatment modalities showed that acoramidis yields the greatest reduction in monomer efflux (96% in ATTRwt, 95% in ATTRv) due to rapid, near‐complete stabilization of TTR. This framework enables quantitative interrogation of the disease system and principled comparisons across modalities that may help inform treatment selection.
- 24 July 2020
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 369 (6502) , 390-+
Simultaneous cross-evaluation of heterogeneous E. coli datasets via mechanistic simulation
Testing biochemical data by simulation: Can a bacterial cell model vet large datasets from disparate sources? Macklin et al. explored whether a comprehensive mathematical model can be used to verify or find conflicts in massive amounts of data that have been reported for the bacterium Escherichia coli , produced in thousands of papers from hundreds of labs. Although most data were consistent, there were data that could not accommodate known biological results, such as insufficient output of RNA polymerases and ribosomes to produce measured cell-doubling times. Other analyses showed that for some essential proteins, no RNA may be transcribed or translated in a cell's lifetime, but viability can be maintained without certain enzymes through a pool of stable metabolites produced earlier. Science , this issue p. eaav3751
- 24 July 2020
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 369 (6502) , 390-+
Simultaneous cross-evaluation of heterogeneous E. coli datasets via mechanistic simulation
Testing biochemical data by simulation: Can a bacterial cell model vet large datasets from disparate sources? Macklin et al. explored whether a comprehensive mathematical model can be used to verify or find conflicts in massive amounts of data that have been reported for the bacterium Escherichia coli , produced in thousands of papers from hundreds of labs. Although most data were consistent, there were data that could not accommodate known biological results, such as insufficient output of RNA polymerases and ribosomes to produce measured cell-doubling times. Other analyses showed that for some essential proteins, no RNA may be transcribed or translated in a cell's lifetime, but viability can be maintained without certain enzymes through a pool of stable metabolites produced earlier. Science , this issue p. eaav3751